Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Cardiff Oncology ( (CRDF) ).
On April 9, 2026, Cardiff Oncology announced that interim CEO and board member Mani Mohindru, PhD, has been appointed President and Chief Executive Officer, while industry veterans Josh Muntner and Ajay Aggarwal, MD, MBA, were named Chief Financial Officer and Chief Operating Officer, effective April 6 and April 27, respectively. The company also granted Muntner an inducement stock option for 486,650 shares, underscoring its push to assemble a seasoned executive team.
The leadership changes are intended to support Cardiff Oncology’s next phase of growth and execution around onvansertib, its lead PLK1 inhibitor being advanced in first-line RAS-mutant metastatic colorectal cancer. With Mohindru’s strategic oversight, Muntner’s capital markets and financing experience, and Aggarwal’s clinical development expertise, the company aims to strengthen operational capabilities and better navigate key clinical and financial inflection points that are critical for its oncology pipeline and stakeholders.
The most recent analyst rating on (CRDF) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Cardiff Oncology stock, see the CRDF Stock Forecast page.
Spark’s Take on CRDF Stock
According to Spark, TipRanks’ AI Analyst, CRDF is a Neutral.
The score is primarily constrained by weak financial performance (minimal revenue, large ongoing losses, and sustained cash burn with shrinking equity), reinforced by bearish technical momentum (below key moving averages and negative MACD). Offsetting factors include a low-debt balance sheet and positive program-related corporate updates that could improve prospects if regulatory/clinical milestones are achieved.
To see Spark’s full report on CRDF stock, click here.
More about Cardiff Oncology
Cardiff Oncology, Inc. is a clinical-stage biotechnology company focused on developing innovative cancer therapies based on PLK1 inhibition, a validated oncology target. Its lead asset, onvansertib, is an oral PLK1 inhibitor in a Phase 2 trial for first-line treatment of RAS-mutated metastatic colorectal cancer, and is also being studied in other PLK1-driven, hard-to-treat tumors through investigator-initiated trials.
The company targets tumor vulnerabilities to overcome treatment resistance and improve clinical outcomes in a large, underserved patient population with high unmet medical need. By concentrating on PLK1-driven cancers and advancing onvansertib across multiple indications, Cardiff Oncology aims to establish a meaningful presence in the oncology therapeutics market and position itself as a leader in next-generation targeted cancer treatments.
Average Trading Volume: 1,050,433
Technical Sentiment Signal: Sell
Current Market Cap: $106.6M
Find detailed analytics on CRDF stock on TipRanks’ Stock Analysis page.